Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Blood Metabolomic Measures Associate With Present and Future Glycemic Control in Type 2 Diabetes.

't Hart, Leen M; Vogelzangs, Nicole; Mook-Kanamori, Dennis O; Brahimaj, Adela; Nano, Jana; van der Heijden, Amber A W A; Willems van Dijk, Ko; Slieker, Roderick C; Steyerberg, Ewout W; Ikram, M Arfan; Beekman, Marian; Boomsma, Dorret I; van Duijn, Cornelia M; Slagboom, P Eline; Stehouwer, Coen D A; Schalkwijk, Casper G; Arts, Ilja C W; Dekker, Jacqueline M; Dehghan, Abbas; Muka, Taulant; van der Kallen, Carla J H; Nijpels, Giel; van Greevenbroek, Marleen M J.
J Clin Endocrinol Metab; 103(12): 4569-4579, 2018 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-30113659

OBJECTIVE:

We studied whether blood metabolomic measures in people with type 2 diabetes (T2D) are associated with insufficient glycemic control and whether this association is influenced differentially by various diabetes drugs. We then tested whether the same metabolomic profiles were associated with the initiation of insulin therapy.

METHODS:

A total of 162 metabolomic measures were analyzed using a nuclear magnetic resonance-based method in people with T2D from four cohort studies (n = 2641) and one replication cohort (n = 395). Linear and logistic regression analyses with adjustment for potential confounders, followed by meta-analyses, were performed to analyze associations with hemoglobin A1c levels, six glucose-lowering drug categories, and insulin initiation during a 7-year follow-up period (n = 698).

RESULTS:

After Bonferroni correction, 26 measures were associated with insufficient glycemic control (HbA1c >53 mmol/mol). The strongest association was with glutamine (OR, 0.66; 95% CI, 0.61 to 0.73; P = 7.6 × 10-19). In addition, compared with treatment-naive patients, 31 metabolomic measures were associated with glucose-lowering drug use (representing various metabolite categories; P ≤ 3.1 × 10-4 for all). In drug-stratified analyses, associations with insufficient glycemic control were only mildly affected by different glucose-lowering drugs. Five of the 26 metabolomic measures (apolipoprotein A1 and medium high-density lipoprotein subclasses) were also associated with insulin initiation during follow-up in both discovery and replication. The strongest association was observed for medium high-density lipoprotein cholesteryl ester (OR, 0.54; 95% CI, 0.42 to 0.71; P = 4.5 × 10-6).

CONCLUSION:

Blood metabolomic measures were associated with present and future glycemic control and might thus provide relevant cues to identify those at increased risk of treatment failure.
Selo DaSilva